AU2017323504A1 - Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same - Google Patents
Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same Download PDFInfo
- Publication number
- AU2017323504A1 AU2017323504A1 AU2017323504A AU2017323504A AU2017323504A1 AU 2017323504 A1 AU2017323504 A1 AU 2017323504A1 AU 2017323504 A AU2017323504 A AU 2017323504A AU 2017323504 A AU2017323504 A AU 2017323504A AU 2017323504 A1 AU2017323504 A1 AU 2017323504A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- crystals
- liquid
- oltipraz
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611031045 | 2016-09-12 | ||
| IN201611031045 | 2016-09-12 | ||
| US201662412681P | 2016-10-25 | 2016-10-25 | |
| US62/412,681 | 2016-10-25 | ||
| PCT/IB2017/001312 WO2018047013A1 (en) | 2016-09-12 | 2017-09-12 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017323504A1 true AU2017323504A1 (en) | 2019-05-02 |
| AU2017323504A8 AU2017323504A8 (en) | 2019-06-06 |
Family
ID=60569947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017323504A Abandoned AU2017323504A1 (en) | 2016-09-12 | 2017-09-12 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11426403B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3509642A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2019531344A (cg-RX-API-DMAC10.html) |
| KR (1) | KR102658015B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN109996562A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017323504A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| AU2017322544B2 (en) * | 2016-09-12 | 2022-06-02 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| CA2408152A1 (en) | 2000-05-05 | 2001-11-15 | Wisconsin Alumni Research Foundation | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| US7012148B2 (en) | 2001-09-25 | 2006-03-14 | Trustees Of Dartmouth College | Compositions and methods for thionation during chemical synthesis reactions |
| US7199122B2 (en) | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| JP2005522446A (ja) | 2002-02-13 | 2005-07-28 | ソルベイ・フアルマ | 肺癌の化学予防におけるアネトールジチオールチオンの使用 |
| KR100491318B1 (ko) | 2002-11-26 | 2005-05-24 | 씨제이 주식회사 | 올티프라즈(Oltipraz) 제조방법 |
| ATE357932T1 (de) | 2003-12-22 | 2007-04-15 | Alcon Inc | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie |
| KR100629771B1 (ko) | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| PL2486942T3 (pl) * | 2004-11-24 | 2019-05-31 | Meda Pharmaceuticals Inc | Kompozycje zawierające azelastynę oraz sposoby ich stosowania |
| FR2879444B1 (fr) | 2004-12-22 | 2007-05-18 | Oreal | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie |
| US20070036733A1 (en) | 2005-08-12 | 2007-02-15 | Takasago International Corp. (Usa) | Sensation masking composition |
| CN101257949B (zh) | 2005-08-15 | 2011-01-19 | 奇华顿股份有限公司 | 清凉化合物 |
| US7803353B2 (en) | 2006-03-29 | 2010-09-28 | The Procter & Gamble Company | Oral care compositions having improved consumer aesthetics and taste |
| GB0704718D0 (en) | 2007-03-12 | 2007-04-18 | Prendergast Patrick T | Compounds and methods for preventing and treating mucositis |
| ATE540667T1 (de) | 2007-06-13 | 2012-01-15 | Givaudan Sa | Verbindungen mit kühlender wirkung |
| US20110003747A1 (en) | 2007-07-20 | 2011-01-06 | Coloumbe Pierre A | Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
| WO2009099830A2 (en) | 2008-01-31 | 2009-08-13 | Mcneil-Ppc, Inc. | Edible film-strips for immediate release of active ingredients |
| US8142806B2 (en) | 2008-03-10 | 2012-03-27 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| US8858995B2 (en) | 2008-03-10 | 2014-10-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| KR101057485B1 (ko) | 2008-08-04 | 2011-08-17 | 서울대학교산학협력단 | 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물 |
| WO2010128026A2 (en) | 2009-05-05 | 2010-11-11 | Givaudan Sa | Organic compounds |
| CN102451469A (zh) * | 2010-10-26 | 2012-05-16 | 沈阳药科大学 | 一类用于难溶性药物纳米系统的高效稳定剂 |
| CA2835293C (en) | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| EP2757887B1 (en) | 2011-09-22 | 2017-04-26 | VIIV Healthcare UK Limited | Pyrrolopyridinone compounds and methods for treating hiv |
| US10500282B2 (en) * | 2012-12-19 | 2019-12-10 | Kashiv Biosciences, Llc | Supersaturated stabilized nanoparticles for poorly soluble drugs |
| WO2015023889A1 (en) | 2013-08-16 | 2015-02-19 | Luminus Biosciences Inc. | Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease |
| EP3110510A1 (en) | 2014-02-27 | 2017-01-04 | The Procter & Gamble Company | Oral care compositions with a reduced bitter taste perception |
| US20160376259A1 (en) * | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for Preparing Oltipraz |
| WO2016207914A2 (en) | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for preparing oltipraz |
| ITUB20159655A1 (it) | 2015-12-23 | 2017-06-23 | Bormioli Rocco Spa | Capsula di sicurezza di un contenitore. |
| ITUA20162141A1 (it) | 2016-03-31 | 2017-10-01 | Bormioli Pharma Spa | Capsula di chiusura |
| AU2017322544B2 (en) * | 2016-09-12 | 2022-06-02 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
| KR20180123796A (ko) | 2017-05-10 | 2018-11-20 | 서울대학교산학협력단 | Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법 |
-
2017
- 2017-09-12 EP EP17808567.6A patent/EP3509642A1/en active Pending
- 2017-09-12 JP JP2019535993A patent/JP2019531344A/ja active Pending
- 2017-09-12 AU AU2017323504A patent/AU2017323504A1/en not_active Abandoned
- 2017-09-12 KR KR1020197010583A patent/KR102658015B1/ko active Active
- 2017-09-12 CN CN201780069787.9A patent/CN109996562A/zh active Pending
-
2019
- 2019-03-12 US US16/351,058 patent/US11426403B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3509642A1 (en) | 2019-07-17 |
| US20190209556A1 (en) | 2019-07-11 |
| AU2017323504A8 (en) | 2019-06-06 |
| US11426403B2 (en) | 2022-08-30 |
| CN109996562A (zh) | 2019-07-09 |
| JP2019531344A (ja) | 2019-10-31 |
| KR102658015B1 (ko) | 2024-05-21 |
| KR20190089852A (ko) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018047013A1 (en) | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same | |
| US20210052580A1 (en) | Combination Compositions and Therapies Comprising 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, and Methods of Making and Using Same | |
| US11931321B2 (en) | Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same | |
| DK2600850T3 (en) | PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NOCICEPTIVE PAIN | |
| RU2589830C2 (ru) | ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН | |
| WO2018047002A1 (en) | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same | |
| JP2023113634A (ja) | 4-メチル-5-(ピラジン-2-イル)-3h-1,2-ジチオール-3-チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法 | |
| US11426403B2 (en) | Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same | |
| US9326977B2 (en) | Anti-inflammatory compounds | |
| CN121568678A (zh) | 局部抗氧化剂组合物及其使用方法 | |
| CN105434409A (zh) | 组合物、组合物的用途及制造方法 | |
| US11135220B1 (en) | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione | |
| JP4590224B2 (ja) | トラニラストまたは薬理学的に許容される塩を含有する懸濁性医薬組成物 | |
| CN118593450A (zh) | 氨磷汀复合脂质纳米粒的制备方法及其应用 | |
| HK40073161B (en) | Compositions and methods for treating central nervous system disorders | |
| HK1183611A (en) | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| HK1183611B (en) | Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 33 , NO 16 , PAGE(S) 2369 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ST IP HOLDING AG, APPLICATION NO. 2017323504, UNDER INID (72) CORRECT THE CO-INVENTOR TO BERNER, BRET |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |